| Protocol |
Title |
Status |
Contact |
| 103797 |
Phase 2/3 Study of Navtemadlin (MDM2i) in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer |
OPEN TO ACCRUAL |
 |
| 103979 |
Phase I trial of Methotrexate, Rituximab, Lenalidomode, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma |
OPEN TO ACCRUAL |
|
| 103517 |
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer |
OPEN TO ACCRUAL |
|
| 103948 |
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA, IIIB (N2) Non-Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
| 103739 |
A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications |
OPEN TO ACCRUAL |
|
| 104046 |
NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial |
OPEN TO ACCRUAL |
|
| 104039 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study of AK117 or Placebo in Combination with Azacitidine in Patients With Newly Diagnosed Higher-Risk Myelodysplastic Syndromes |
OPEN TO ACCRUAL |
|
| 103898 |
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
OPEN TO ACCRUAL |
|
| 103923 |
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
| 103866 |
Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-Risk Stage II-IV Melanoma |
OPEN TO ACCRUAL |
|
| 103478 |
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) |
OPEN TO ACCRUAL |
|
| 103974 |
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors |
OPEN TO ACCRUAL |
|
| 103950 |
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
| 103985 |
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score 25 |
OPEN TO ACCRUAL |
|
| 103994 |
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck |
OPEN TO ACCRUAL |
|
| 103892 |
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy |
OPEN TO ACCRUAL |
|
| 103743 |
A Phase 1b Dose Escalation Study of AV-380 in Combination with Chemotherapy or Immunotherapy in Cancer Patients with Elevated GDF-15 Levels Colorectal Cancer, NSCLC, Pancreatic Cancer |
OPEN TO ACCRUAL |
|
| 103683 |
GOG-3076 a Phase 3 Trial in Platinum-Resistant/Refractory Ovarian Cancer |
OPEN TO ACCRUAL |
|
| 103747 |
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal
Carcinoma |
OPEN TO ACCRUAL |
|
| 103984 |
OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy |
OPEN TO ACCRUAL |
|